PDGFRA and hepatocellular carcinoma: Lenvatinib is a multi-kinase inhibitor approved in 2018 as first-line treatment for advanced HCC (7), exerting its inhibitory activity against vascular endothelial growth factor receptors (VEGFR1-3), fibroblast growth factor receptors (FGFR1-4), platelet-derived growth factor receptor alpha (PDGFR-α), c-KIT, and RET (8).